Your session is about to expire
← Back to Search
Once Daily Dosing for Kidney Transplant (OnceDaily Trial)
OnceDaily Trial Summary
This trial is testing whether giving all medications once a day, instead of the current twice-daily schedule, will improve patient adherence and satisfaction.
- Kidney Failure
OnceDaily Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.OnceDaily Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You have had treatment to reduce your body's reaction to certain proteins or blood type differences in the past.Your Panel Reactive Antibody (PRA) level is 30% or higher before the transplantation.People who are at least 12 years old and adults who are at least 18 years old.You are taking medications like tacrolimus, cyclosporin, or Advagraf.You have only had one transplant and are considered low risk by the main doctor before being asked to join the study.Your transplanted kidney is not working well, and you have experienced rejection or other specific kidney problems in the past.You have an ongoing infection or are getting treated for a long-term infection.Your kidneys are not filtering blood properly.You have any type of cancer that is currently growing or spreading, except for non-melanoma skin cancer.You are taking too many different medications to switch to a once-a-day medication.You must have received a kidney transplant at least 12 months ago.You have been taking a specific amount of mycophenolate medication daily for the past 3 months, and it's important to stick to the prescribed amount.You are taking a different medication than mycophenolate mofetil or mycophenolate sodium, or you are not taking any of these drugs.Children who are at least 14 years old and receiving treatment at British Columbia Children's Hospital.You had a kidney transplant at British Columbia Children's Hospital at least 12 months ago.
- Group 1: Conversion to once daily dosing
- All Individual Drugs Already Approved - Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
- Approved for 30 Other Conditions - This treatment demonstrated efficacy for 30 other conditions.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Have other investigations delved into transforming non-immunosuppressant medicines to once daily consumption?
"Currently, 580 clinical trials of non-immunosuppressant drugs in Phase 3 are being conducted to assess the potential for once daily dosing. Of these studies, 129 are located within Philadelphia, Pennsylvania with a further 17 934 sites operating similar research worldwide."
How many participants have been accepted for this clinical research?
"This clinical trial is no longer recruiting participants. It was first posted in April of 2016 and last updated in November 2022. For those seeking other medical trials, 180 studies with kidney failure are actively enrolling patients, along with 580 research projects for the conversion of non-immunosuppressant drugs to once daily dosing."
Is this trial currently seeking participants?
"Unfortunately, this trial has stopped accepting new participants. It was posted on April 1st 2016 and last updated November 4th 2022; however, there are still 180 trials actively admitting patients suffering kidney failure and 580 studies recruiting for the conversion of non-immunosuppressant drugs to once daily intake."
What therapeutic conditions is the transition of non-immunosuppressant drugs to a single daily dose usually employed for?
"Conversion of non-immunosuppressant drugs to a single daily dose is the preferred approach for treating thyroiditis. This protocol can also be used with success in cases of dermatitis, atopic, bulla and ulcerative colitis."
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger